Skip to main content
NCBI home page
Infectious Diseases in Obstetrics and Gynecology logoLink to Infectious Diseases in Obstetrics and Gynecology
. 2003;11(4):181–189. doi: 10.1080/10647440300025519

The Efficacy of Vaginal Clindamycin for the Treatment of Abnormal Genital Tract Flora in Pregnancy

Ronald F Lamont 1,5,6,✉, Brian M Jones 2, Debashis Mandal 3, Philip E Hay 4, Marie Sheehan 5
PMCID: PMC1852293  PMID: 15108863

Abstract

Objective: To assess the efficacy of 2% clindamycin vaginal cream (CVC) to treat bacterial vaginosis (BV) in pregnancy.

Methods: A prospective, randomized, double-blind, placebo-controlled, tricenter study. Four hundred and four women with BV on Gram stain at their first antenatal clinic visit were randomized to receive a 3-day course of 2% CVC or placebo. The outcome was assessed using an intention to treat analysis at 3 weeks and 6 weeks post-treatment according to three different diagnostic methods based on five criteria (Gram stain and all four elements of clinical composite criteria: vaginal discharge, abnormal vaginal pH, clue cells, amine odor), three criteria (vaginal pH, clue cells, amine odor) or two criteria (clue cells and amine odor) to reflect stringency of diagnosis, historical precedence and government agency recommendations respectively.

Results: Using five diagnostic criteria, 18% of CVC patients were cured and 70.8% either cured and/or improved compared to 1.6% and 12% of placebo patients respectively (p < 0.0001). Using three diagnostic criteria, 44.8% of CVC patients were cured and 77.3% were either cured and/or improved compared to 9.3% and 28.8% of placebo patients respectively (p < 0.0001). Using two diagnostic criteria, 75.0% of CVC patients were cured compared to 18.0% of placebo patients (p < 0.0001). Recurrence rates in those CVC patients successfully treated were approximately 6% at 6 weeks post baseline and 10% at 28 to 34 weeks gestation.

Conclusions: A 3-day course of CVC appears to be well tolerated by the mother and statistically significantly more efficacious than placebo in the treatment of BV during the second trimester of pregnancy.

Full Text

The Full Text of this article is available as a PDF (402.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahmed-Jushuf I. H., Shahmanesh M., Arya O. P. The treatment of bacterial vaginosis with a 3 day course of 2% clindamycin cream: results of a multicentre, double blind, placebo controlled trial. B V Investigators Group. Genitourin Med. 1995 Aug;71(4):254–256. doi: 10.1136/sti.71.4.254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Amsel R., Totten P. A., Spiegel C. A., Chen K. C., Eschenbach D., Holmes K. K. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983 Jan;74(1):14–22. doi: 10.1016/0002-9343(83)91112-9. [DOI] [PubMed] [Google Scholar]
  3. Gibbs R. S. Chorioamnionitis and bacterial vaginosis. Am J Obstet Gynecol. 1993 Aug;169(2 Pt 2):460–462. doi: 10.1016/0002-9378(93)90341-f. [DOI] [PubMed] [Google Scholar]
  4. Hay P. E., Lamont R. F., Taylor-Robinson D., Morgan D. J., Ison C., Pearson J. Abnormal bacterial colonisation of the genital tract and subsequent preterm delivery and late miscarriage. BMJ. 1994 Jan 29;308(6924):295–298. doi: 10.1136/bmj.308.6924.295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hay P. E., Taylor-Robinson D., Lamont R. F. Diagnosis of bacterial vaginosis in a gynaecology clinic. Br J Obstet Gynaecol. 1992 Jan;99(1):63–66. doi: 10.1111/j.1471-0528.1992.tb14395.x. [DOI] [PubMed] [Google Scholar]
  6. Hillier S., Krohn M. A., Watts D. H., Wolner-Hanssen P., Eschenbach D. Microbiologic efficacy of intravaginal clindamycin cream for the treatment of bacterial vaginosis. Obstet Gynecol. 1990 Sep;76(3 Pt 1):407–413. [PubMed] [Google Scholar]
  7. Kent H. L. Epidemiology of vaginitis. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1168–1176. doi: 10.1016/s0002-9378(12)90722-x. [DOI] [PubMed] [Google Scholar]
  8. Kurki T., Sivonen A., Renkonen O. V., Savia E., Ylikorkala O. Bacterial vaginosis in early pregnancy and pregnancy outcome. Obstet Gynecol. 1992 Aug;80(2):173–177. [PubMed] [Google Scholar]
  9. Lamont R. F. Antibiotics for the prevention of preterm birth. N Engl J Med. 2000 Feb 24;342(8):581–583. doi: 10.1056/NEJM200002243420810. [DOI] [PubMed] [Google Scholar]
  10. Lamont Ronald F., Duncan Sheila L. B., Mandal Debashis, Bassett Paul. Intravaginal clindamycin to reduce preterm birth in women with abnormal genital tract flora. Obstet Gynecol. 2003 Mar;101(3):516–522. doi: 10.1016/s0029-7844(02)03054-5. [DOI] [PubMed] [Google Scholar]
  11. Livengood C. H., 3rd, Thomason J. L., Hill G. B. Bacterial vaginosis: diagnostic and pathogenetic findings during topical clindamycin therapy. Am J Obstet Gynecol. 1990 Aug;163(2):515–520. doi: 10.1016/0002-9378(90)91187-h. [DOI] [PubMed] [Google Scholar]
  12. Mason M. R., Adrinkra P. E., Lamont R. F. Prophylactic administration of clindamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased risk: a randomised placebo-controlled double-blind trial. BJOG. 2000 Feb;107(2):295–296. doi: 10.1111/j.1471-0528.2000.tb11707.x. [DOI] [PubMed] [Google Scholar]
  13. McGregor J. A., French J. I., Jones W., Milligan K., McKinney P. J., Patterson E., Parker R. Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream. Am J Obstet Gynecol. 1994 Apr;170(4):1048–1060. doi: 10.1016/s0002-9378(94)70098-2. [DOI] [PubMed] [Google Scholar]
  14. Newton E. R., Prihoda T. J., Gibbs R. S. A clinical and microbiologic analysis of risk factors for puerperal endometritis. Obstet Gynecol. 1990 Mar;75(3 Pt 1):402–406. [PubMed] [Google Scholar]
  15. Nugent R. P., Krohn M. A., Hillier S. L. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol. 1991 Feb;29(2):297–301. doi: 10.1128/jcm.29.2.297-301.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Riduan J. M., Hillier S. L., Utomo B., Wiknjosastro G., Linnan M., Kandun N. Bacterial vaginosis and prematurity in Indonesia: association in early and late pregnancy. Am J Obstet Gynecol. 1993 Jul;169(1):175–178. doi: 10.1016/0002-9378(93)90157-e. [DOI] [PubMed] [Google Scholar]
  17. Rosenstein I. J., Morgan D. J., Lamont R. F., Sheehan M., Doré C. J., Hay P. E., Taylor-Robinson D. Effect of intravaginal clindamycin cream on pregnancy outcome and on abnormal vaginal microbial flora of pregnant women. Infect Dis Obstet Gynecol. 2000;8(3-4):158–165. doi: 10.1155/S1064744900000211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Rosenstein I. J., Morgan D. J., Sheehan M., Lamont R. F., Taylor-Robinson D. Bacterial vaginosis in pregnancy: distribution of bacterial species in different gram-stain categories of the vaginal flora. J Med Microbiol. 1996 Aug;45(2):120–126. doi: 10.1099/00222615-45-2-120. [DOI] [PubMed] [Google Scholar]
  19. Thomason J. L., Gelbart S. M., Anderson R. J., Walt A. K., Osypowski P. J., Broekhuizen F. F. Statistical evaluation of diagnostic criteria for bacterial vaginosis. Am J Obstet Gynecol. 1990 Jan;162(1):155–160. doi: 10.1016/0002-9378(90)90839-y. [DOI] [PubMed] [Google Scholar]
  20. Vermeulen G. M., Bruinse H. W. Prophylactic administration of clindamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomised placebo-controlled double-blind trial. Br J Obstet Gynaecol. 1999 Jul;106(7):652–657. doi: 10.1111/j.1471-0528.1999.tb08363.x. [DOI] [PubMed] [Google Scholar]
  21. Vermeulen G. M., van Zwet A. A., Bruinse H. W. Changes in the vaginal flora after two percent clindamycin vaginal cream in women at high risk of spontaneous preterm birth. BJOG. 2001 Jul;108(7):697–700. doi: 10.1111/j.1471-0528.2001.00175.x. [DOI] [PubMed] [Google Scholar]

Articles from Infectious Diseases in Obstetrics and Gynecology are provided here courtesy of Wiley

RESOURCES